Human Papillomavirus Prevalence and Herd Immunity after Introduction of Vaccination Program, Scotland, 2009-2013.
about
Human papillomavirus vaccination guideline update: American Cancer Society guideline endorsementHPV immunisation and increased uptake of cervical screening in Scottish women; observational study of routinely collected national data.Cost analysis of Human Papillomavirus-related cervical diseases and genital warts in SwazilandHuman papillomavirus (HPV) in young women in Britain: Population-based evidence of the effectiveness of the bivalent immunisation programme and burden of quadrivalent and 9-valent vaccine types.Human Papilloma Virus (HPV) Oral Prevalence in Scotland (HOPSCOTCH): A Feasibility Study in Dental Settings.HPV immunisation and cervical screening--confirmation of changed performance of cytology as a screening test in immunised women: a retrospective population-based cohort study.Response letter regarding the letter to the editors by Brown et al.Population-Level Effects of Human Papillomavirus Vaccination Programs on Infections with Nonvaccine Genotypes.Different Challenges in Eliminating HPV16 Compared to Other Types: A Modeling Study.Cervical cancer screening in the era of HPV vaccination: A review of shifting paradigms in cytopathology.Worldwide burden of cancer attributable to HPV by site, country and HPV type.Reduction in colposcopy workload and associated clinical activity following human papillomavirus (HPV) catch-up vaccination programme in Scotland: an ecological study.Progress in HPV vaccination in low- and lower-middle-income countries.Sustained Immunogenicity of 2-dose Human Papillomavirus 16/18 AS04-adjuvanted Vaccine Schedules in Girls Aged 9-14 Years: A Randomized Trial.Use of HPV testing for cervical screening in vaccinated women--Insights from the SHEVa (Scottish HPV Prevalence in Vaccinated Women) study.Prevalence of Human Papillomavirus Among Females After Vaccine Introduction-National Health and Nutrition Examination Survey, United States, 2003-2014.Fraction of high-grade cervical intraepithelial lesions attributable to genotypes targeted by a nonavalent HPV vaccine in Galicia, Spain.Who's Not Protected in the Herd? Factors Associated with Vaccine-Type HPV in Unvaccinated Women.Low prevalence of vaccine-type HPV infections in young women following the implementation of a school-based and catch-up vaccination in Quebec, Canada.Impact of HPV vaccination with Gardasil® in Switzerland.Differences between vaccinated and unvaccinated women explain increase in non-vaccine-type human papillomavirus in unvaccinated women after vaccine introduction.Impact of gender-neutral or girls-only vaccination against human papillomavirus-Results of a community-randomized clinical trial (I).Determining the HPV vaccine schedule for a HIV-infected population in sub Saharan Africa, a commentaryCervical cancer prevention: An Italian scenario between organised screening and human papillomaviruses vaccinationImpact of HPV-vaccination on outcome of cervical cytology screening in Denmark - a register based cohort studyDirect, indirect and total effectiveness of bivalent HPV vaccine in women in Galicia, Spain
P2860
Q28069669-914D1673-A54C-407D-95EB-92DFAA80AC41Q31038776-C0064819-8EE8-4697-B8AF-9ADEC42D0139Q33713018-63D9A8C7-8775-4F8A-896A-5E0D8D936D2FQ33774640-505292B1-F7C0-4687-AAA6-B568EF79A07CQ36197117-5A98A049-1DA3-4904-9346-4F89944AA05DQ36662008-E2E6DF4D-BD9C-422D-BB5B-04F6D5CC77A2Q37135422-7E63241A-01B9-4B58-B48B-71C496E96533Q37288157-E4EF6AAB-9966-4241-B475-072ED8BC53BCQ38599579-5D9CC1B1-11FA-4418-99F3-7C6D012C81BAQ38673879-1F7D40D9-00B7-4EB5-96EE-C302FD597333Q38859779-E375131A-8AEF-4153-9C69-5FCCD76BF086Q39012586-09C00546-3F32-4D24-B8EC-AFD699A91AC4Q39158741-94B26A78-5842-4BE5-9500-F58A508AF4DDQ40168801-2164BD86-46DD-4A5E-9F45-EC8DC65CA96DQ40805660-81125D01-013A-4F82-ADC9-6026C7913B11Q41933605-75EEDE71-BF36-4B85-9045-364DA8E28D8DQ44841725-671E5656-90A8-4BAE-937F-B4DF112A6548Q46775905-39AA47F1-A8E1-41E6-A45E-26C742385BFDQ47239227-D594036B-18B4-4486-8C32-71A30141C5E1Q47257772-E049A60A-3F30-47A4-B3FC-C168B7476090Q47422435-C98B5C62-2C69-4B2D-B263-DE5DC93E9684Q47603242-7C64D781-B6AC-4457-89B3-5C50BC881E3AQ56987144-B8EE8D5A-2B93-4BBF-8E2B-23364BBB9CAAQ58764089-12B499EC-AF2B-4D7E-B30D-5B1A4D45294BQ58766182-72FCBE89-5605-4AB7-8576-36CA06D12D9DQ58802518-ADC8EAAB-E29B-4F8C-B17D-F6F3BDDED520
P2860
Human Papillomavirus Prevalence and Herd Immunity after Introduction of Vaccination Program, Scotland, 2009-2013.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Human Papillomavirus Prevalenc ...... Program, Scotland, 2009-2013.
@ast
Human Papillomavirus Prevalenc ...... Program, Scotland, 2009-2013.
@en
type
label
Human Papillomavirus Prevalenc ...... Program, Scotland, 2009-2013.
@ast
Human Papillomavirus Prevalenc ...... Program, Scotland, 2009-2013.
@en
prefLabel
Human Papillomavirus Prevalenc ...... Program, Scotland, 2009-2013.
@ast
Human Papillomavirus Prevalenc ...... Program, Scotland, 2009-2013.
@en
P2093
P2860
P356
P1476
Human Papillomavirus Prevalenc ...... n Program, Scotland, 2009-2013
@en
P2093
Chris Robertson
Jiafeng Pan
Kate Cuschieri
Kevin G J Pollock
Ross L Cameron
Syed Ahmed
Timothy Palmer
P2860
P356
10.3201/EID2201.150736
P577
2016-01-01T00:00:00Z